Your search for: 'author:("Rosen, Allyson C.")' has returned 10 results. (0.027s) Save search

Authors: Rosen, Allyson C.

Article Type: Review Article

DOI: 10.3233/JAD-141293

Citation: Journal of Alzheimer's Disease, vol. 41, no. 3, pp. 663-664, 2014

Authors: Rosen, Allyson C.

Article Type: Introduction

Abstract: Advances in biomarkers, genetics, and other data used as dementia risk evidence (DRE) are increasingly informing clinical diagnosis and management. The purpose of this Mini-Forum is to provide a solutions-based discussion of the ethical and legal gaps and practical questions about how to use and communicate these data. Investigators often use DRE in research. When participants ask for their personal results, investigators have concerns. Will data that was intended to study groups be valid for individuals? Will sharing data cause distress? Debates around sharing DRE became heated when blood-based amyloid tests and amyloid reducing drugs appeared poised to enable clinicians …easily to identify people with elevated brain amyloid and reduce it with a drug. Such an approach would transform the traditional role of DRE from investigational to foundational; however, then the high costs, uncertain clinical benefits and risks of the therapy led to an urgent need for education to support clinical decision making. Further complicating DRE use are direct to consumer genetic testing and increasingly available biomarker testing. Withholding DRE becomes less feasible and public education around responsible use and understanding become vital. A critical answer to these legal and ethical issues is supporting education that clearly delineates known risks, benefits, and gaps in knowledge, and communication to promote understanding among researchers, clinicians, patients, and all stakeholders. This paper provides an overview and identifies general concepts and resource documents that support more informed discussions for individuals and interdisciplinary groups. Show more

Keywords: Alzheimer’s disease, biomarkers, diagnosis, ethics, genetics, imaging, magnetic resonance imaging, positron emission tomography, risk, uncertainty

DOI: 10.3233/JAD-220722

Citation: Journal of Alzheimer's Disease, vol. 90, no. 3, pp. 933-944, 2022

Authors: Possin, Katherine L. | Rosen, Allyson C.

Article Type: Article Commentary

Abstract: O’Caoimh et al. demonstrated that caregivers or family members could administer and score a brief cognitive screening instrument and detect cognitive impairment with comparable accuracy to similar measures administered in-person by trained staff. This novel approach challenges us to consider the boundaries of how caregivers or other family members are used in remote testing. We discuss the potential risks of administration bias, test integrity, and impacts on the patient and caregiver or family member, and we recommend further research before incorporating this practice into routine clinical or research use.

Keywords: Cognitive assessment, ethics, mild cognitive impairment, neuropsychology

DOI: 10.3233/JAD-220862

Citation: Journal of Alzheimer's Disease, vol. 90, no. 4, pp. 1429-1431, 2022

Authors: Rosen, Allyson C. | Ashford, John Wesson | Perry, George

Article Type: Review Article

Abstract: There are several points where ethical decision-making has become paralyzed and inefficient as the field of Alzheimer's disease study has advanced. The focus of this review is to highlight these points and several lines of research that can inform ethical decision-making. The goal is to identify barriers and to move toward solutions. Examples of other fields of study that can be particularly useful for innovative ways to study effective ethical decision-making include implementation science and neuroscience of decision-making, as well as therapeutic investigations of other domains such as the human biology and psychology.

DOI: 10.3233/JAD-132762

Citation: Journal of Alzheimer's Disease, vol. 40, no. 2, pp. 233-235, 2014

Authors: Rosen, Allyson C. | Toy, Leslie | Langston, Ashley H.

Article Type: Research Article

Abstract: The potential for successful disease modifying treatments for Alzheimer’s disease (AD) opens up the possibility that there will be a large cohort of patients living with late-stage dementia and poor quality of life. There must thus be a parallel effort to leverage restorative therapies that improve quality of life in these patients. With the potential for stopping the onset of AD in new patients must come a commitment to those patients living with this chronic disability for many more years than first thought. Legal and ethical implications surrounding who makes decisions and equity in receiving care will become increasingly important …if AD is no longer a terminal illness. Show more

Keywords: Alzheimer’s disease, dementia, end of life, hospice, neuroethics, therapy, quality of life

DOI: 10.3233/JAD-181193

Citation: Journal of Alzheimer's Disease, vol. 68, no. 4, pp. 1317-1319, 2019

Authors: Rosen, Allyson C. | Sugiura, Lisa | Kramer, Joel H. | Whitfield-Gabrieli, Susan | Gabrieli, John D.

Article Type: Research Article

Abstract: A randomized pilot experiment examined the neural substrates of response to cognitive training in participants with mild cognitive impairment (MCI). Participants performed exercises previously demonstrated to improve verbal memory and an active control group performed other computer activities. An auditory-verbal fMRI task was conducted before and after the two-month training program. Verbal memory scores improved significantly and left hippocampal activation increased significantly in the experimental group (gains in 5 of 6 participants) relative to the control group (reductions in all 6 participants). Results suggest that the hippocampus in MCI may retain sufficient neuroplasticity to benefit from cognitive training.

Keywords: MRI, dementia, cognition, MCI, mild cognitive impairment, fMRI, functional MRI, cognitive training, hippocampus, medial temporal lobe

DOI: 10.3233/JAD-2011-0009

Citation: Journal of Alzheimer's Disease, vol. 26, no. s3, pp. 349-357, 2011

Authors: Rosen, Allyson C. | Lavacot, James A. | Klee, Victoria | Luria, Yuval | Rumbaugh, Malia

Article Type: Review Article

Abstract: Ethics Review began a decade ago with a mission to identify ethical concerns that hold back innovation and to promote solutions that would move the field forward. Over this time, blood biomarkers for brain pathology and medications that treat that pathology promise to transform research and care. A central problem is that the evidence needed to guide test interpretation and practice is accumulating and there are unanswered questions. At the same time, people living with and at risk for dementia want access to their test results and involvement in their care. We promote dialog among diverse people across many institutions …through collaboration with the Advisory Group on Risk Evidence Education for Dementia (AGREEDementia.org). Over the years Ethics Review continues to publish these dialogs and solutions to overcome the paralysis of indecision and ethical concerns. Show more

Keywords: Alzheimer’s disease, amyloid-beta, blood biomarker, diagnostics, ethics

DOI: 10.3233/JAD-240634

Citation: Journal of Alzheimer's Disease, vol. 100, no. s1, pp. S283-S290, 2024

Authors: Walter, Sarah | Taylor, Angela | Tyrone, Jamie | Langer, Sara | Pagan, John-Richard | Hummel, Cynthia Huling | Wheaton, Bonnie M. | Zallen, Doris T. | Rosen, Allyson C.

Article Type: Editorial

Abstract: This Study Participant’s Bill of Rights is a call to action for researchers in Alzheimer’s disease and related dementias (ADRD) to proactively design clinical studies that provide the option for research participants to learn their individual research results if they choose, and in a manner that ensures study integrity. This Bill of Rights was crafted by a committee of study participants, care partners, representatives of dementia advocacy organizations, and other stakeholders in dementia research for the Advisory Group on Risk Education for Dementia (AGREEDementia). The framework developed by the Multi-Regional Clinical Trials (MRCT) Return of Individual Research Results provides a …useful context for researchers to plan their studies and disclosure. Show more

Keywords: Biomarkers, communication, dementia, disclosure, ethics, genetics, patient rights

DOI: 10.3233/JAD-220810

Citation: Journal of Alzheimer's Disease, vol. 90, no. 3, pp. 945-952, 2022

Authors: Cheng, Jauhtai | Fairchild, J. Kaci | McNerney, M. Windy | Noda, Art | Ashford, J. Wesson | Suppes, Trisha | Chao, Steven Z. | Taylor, Joy | Rosen, Allyson C. | Durazzo, Timothy C. | Lazzeroni, Laura C. | Yesavage, Jerome

Article Type: Research Article

Abstract: Background: Despite decades of research efforts, current treatments for Alzheimer’s disease (AD) are of limited effectiveness and do not halt the progression of the disease and associated cognitive decline. Studies have shown that repetitive transcranial magnetic stimulation (rTMS) may improve cognition. Objective: We conducted a pilot study to investigate the effect of rTMS on cognitive function in Veterans with numerous medical comorbidities. Methods: Participants underwent 20 sessions, over the course of approximately 4 weeks, of 10 Hz rTMS at the left dorsolateral prefrontal cortex with intensity of 120% resting motor threshold. Outcome measures including memory, language, verbal fluency, and executive …functions were acquired at baseline, end of treatment, and 4 months after the last rTMS session. Twenty-six Veterans completed the study (13 in the active rTMS group, 13 in the sham rTMS group). Results: The study protocol was well-tolerated. Active, compared to sham, rTMS showed improved auditory-verbal memory at the end of treatment and at 4-month follow-up. However, the active rTMS group demonstrated a trend in decreased semantic verbal fluency at the end of treatment and at 4-month follow up. Conclusion: These preliminary results show rTMS is safe in general in this elderly Veteran population with multiple co-morbidities. Patients in the sham group showed an expected, slight decline in the California Verbal Learning Test scores over the course of the study, whereas the active treatment group showed a slight improvement at the 4-month post-treatment follow up. These effects need to be confirmed by studies of larger sample sizes. Show more

Keywords: Brain stimulation, california verbal learning test, repetitive transcranial magnetic stimulation, veterans

DOI: 10.3233/JAD-210349

Citation: Journal of Alzheimer's Disease, vol. 85, no. 4, pp. 1593-1600, 2022

Authors: Rosen, Allyson C. | Arias, Jalayne J. | Ashford, J. Wesson | Blacker, Deborah | Chhatwal, Jasmeer P. | Chin, Nathan A. | Clark, Lindsay | Denny, Sharon S. | Goldman, Jill S. | Gleason, Carey E. | Grill, Joshua D. | Heidebrink, Judith L. | Henderson, Victor W. | Lavacot, James A. | Lingler, Jennifer H. | Menon, Malavika | Nosheny, Rachel L. | Oliveira, Fabricio F. | Parker, Monica W. | Rahman-Filipiak, Annalise | Revoori, Anwita | Rumbaugh, Malia C. | Sanchez, Danurys L. | Schindler, Suzanne E. | Schwarz, Christopher G. | Toy, Leslie | Tyrone, Jamie | Walter, Sarah | Wang, Li-san | Wijsman, Ellen M. | Zallen, Doris T. | Aggarwal, Neelum T.

Article Type: Editorial

Abstract: The brain changes of Alzheimer’s disease and other degenerative dementias begin long before cognitive dysfunction develops, and in people with subtle cognitive complaints, clinicians often struggle to predict who will develop dementia. The public increasingly sees benefits to accessing dementia risk evidence (DRE) such as biomarkers, predictive algorithms, and genetic information, particularly as this information moves from research to demonstrated usefulness in guiding diagnosis and clinical management. For example, the knowledge that one has high levels of amyloid in the brain may lead one to seek amyloid reducing medications, plan for disability, or engage in health promoting behaviors to fight …cognitive decline. Researchers often hesitate to share DRE data, either because they are insufficiently validated or reliable for use in individuals, or there are concerns about assuring responsible use and ensuring adequate understanding of potential problems when one’s biomarker status is known. Concerns include warning people receiving DRE about situations in which they might be compelled to disclose their risk status potentially leading to discrimination or stigma. The Advisory Group on Risk Evidence Education for Dementia (AGREEDementia) welcomes all concerned with how best to share and use DRE. Supporting understanding in clinicians, stakeholders, and people with or at risk for dementia and clearly delineating risks, benefits, and gaps in knowledge is vital. This brief overview describes elements that made this group effective as a model for other health conditions where there is interest in unfettered collaboration to discuss diagnostic uncertainty and the appropriate use and communication of health-related risk information. Show more

Keywords: Alzheimer’s disease, amyloid, biomarkers, dementia, genetics

DOI: 10.3233/JAD-220458

Citation: Journal of Alzheimer's Disease, vol. 90, no. 3, pp. 953-962, 2022